Compare Las Vegas Sands Corp. (LVS) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Nuwellis Inc — how do they compare? Las Vegas Sands Corp. trades at $45.95 (market cap $30.36B), while Nuwellis Inc trades at $2.99 (market cap $1.09M). The key difference: Las Vegas Sands Corp. is far larger — about 27853.2× Nuwellis Inc's market cap, and Las Vegas Sands Corp. pays a 2.4% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| LVS | NUWE | |
|---|---|---|
Market Cap | $30.36B | $1.09M |
Sector | Consumer Cyclical | Technology |
52-Week High | $69.49 | $527.46 |
52-Week Low | $44.78 | $2.80 |
Enterprise Value | $42.75B | -$722.58K |
Dividend Yield | 2.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $45.66, up 0.66% on the day, with a bearish technical signal but strong fundamentals. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $0.91 beating expectations. Revenue growth is robust, reaching $13.02B in 2025, and profitability metrics like a 49.59% gross margin and 94.53% ROE are impressive. The company maintains positive cash flow and recently paid a $0.30 dividend. Analyst sentiment is bullish with a $65.18 consensus price target, though technical indicators suggest near-term pressure.
The outlook for LVS is positive based on fundamental strength and analyst optimism, but risks include high debt levels and bearish technical trends. Investment opportunity lies in its earnings momentum and valuation upside, while investors should monitor debt management and market volatility. The stock's current price near support levels may present a entry point if fundamentals hold.
NUWE trades at $3.00, up 5.26% today, following a 35:1 reverse stock split effective June 26, 2026. The company shows a low P/E of 0.06 and P/S of 0.01, but fundamentals are weak with a -217.22% net income margin and negative ROE. Recent news highlights patent awards and pediatric market expansion, yet cash flow remains negative. Analyst coverage is limited with a split buy/hold consensus.
Outlook is speculative; growth depends on successful commercialization of Aquadex therapy and cost management. Key risks include persistent losses, high cash burn, and competitive pressures. Investors should weigh low valuation against execution risks in the medical technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
